Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

In brief

The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).

Key facts

Study ID
NCT06117774
Run by
Amgen
People needed
404
Starts
2024-02-20
Expected to finish
2030-04-20
Last updated by the study team
2026-04-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.